Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 305 participants.
Also called NCT07102628
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 305 participants
- Sponsor
- Registry
-
NCT07102628 -
2025-521670-34
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Australia, Canada, China, France, Germany, Hong Kong SAR China, Hungary, India, Japan, Poland, South Korea, Spain, Switzerland
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT07102628. Randomized; quadruple masking; primary purpose treatment. Start 2025-10-03 (actual); primary completion 2027-01-16 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
- Acronym
- ACS
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Inclisiran
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct07102628- Content hash
b59bb8c6be8d8ce174ea0ceaf49f86d8ef3122b42834212701f57c3276d67366